Q-omics provides the consensus-scored RN7SKP269 profile across patient tissues and cancer cell-line models. RN7SKP269 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RN7SKP269 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, RN7SKP269 RNA expression shows 8,960 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, LUSC, and KIRP as cancer lineages where RN7SKP269 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP269 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP269 survival associations across molecular data types. RN7SKP269 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP269 RNA expression–survival associations across cancer types. High RN7SKP269 expression shows unfavorable associations in LIHC, THCA, KIRC, MESO and COAD, but favorable associations in UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RN7SKP269 RNA expression.
This table summarizes RN7SKP269 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP269. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP269 shows higher tumor expression in LUSC, LUAD, LIHC, HNSC, UCEC and BLCA. The LUSC box plot shows higher RN7SKP269 RNA expression in tumor versus normal tissue (log2 FC = +0.872, t-test p < 0.001).
This table shows molecular features associated with RN7SKP269 in patient tissues and cancer cell lines. In patient samples, RN7SKP269 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
